Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
Authors
Pelzer, UBlanc, J
Melisi, D
Cubillo, A
Von Hoff, D
Wang-Gillam, A
Chen, L
Siveke, J
Wan, Y
Solem, C
Botteman, M
Yang, Y
de Jong, F
Hubner, Richard A
Affiliation
Department of Hematology/Oncology/Tumorimmunology, Charite - Universitatsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, GermanyIssue Date
2017-03-28
Metadata
Show full item recordAbstract
In the NAPOLI-1 Phase 3 trial, nal-IRI+5-fluorouracil and leucovorin (5-FU/LV) significantly improved median overall survival (6.1 vs 4.2 months, P=0.012) and progression-free survival (3.1 vs 1.5 months, P=0.0001) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma patients previously treated with gemcitabine-based therapy. This analysis evaluated between treatment differences in quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST).Citation
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. 2017, Br J CancerJournal
British Journal of CancerDOI
10.1038/bjc.2017.67PubMed ID
28350787Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/bjc.2017.67